Comparing Neurocrine Biosciences (NBIX) and Amarin Corporation PLC (AMRN)
Neurocrine Biosciences (NASDAQ: NBIX) and Amarin Corporation PLC (NASDAQ:AMRN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, institutional ownership and profitability.
This is a summary of current ratings and recommmendations for Neurocrine Biosciences and Amarin Corporation PLC, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Amarin Corporation PLC||0||0||4||0||3.00|
Neurocrine Biosciences currently has a consensus price target of $68.25, suggesting a potential upside of 20.16%. Amarin Corporation PLC has a consensus price target of $8.00, suggesting a potential upside of 143.90%. Given Amarin Corporation PLC’s stronger consensus rating and higher probable upside, analysts plainly believe Amarin Corporation PLC is more favorable than Neurocrine Biosciences.
Volatility and Risk
Neurocrine Biosciences has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, Amarin Corporation PLC has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.
Insider and Institutional Ownership
37.8% of Amarin Corporation PLC shares are held by institutional investors. 4.8% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 3.7% of Amarin Corporation PLC shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Neurocrine Biosciences and Amarin Corporation PLC’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Neurocrine Biosciences||$6.34 million||790.38||-$219.96 million||($2.52)||-22.54|
|Amarin Corporation PLC||$151.31 million||5.87||-$57.34 million||($0.31)||-10.58|
Amarin Corporation PLC has higher revenue and earnings than Neurocrine Biosciences. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Amarin Corporation PLC, indicating that it is currently the more affordable of the two stocks.
This table compares Neurocrine Biosciences and Amarin Corporation PLC’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Amarin Corporation PLC||-51.42%||N/A||-39.14%|
Amarin Corporation PLC beats Neurocrine Biosciences on 9 of the 13 factors compared between the two stocks.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.
Amarin Corporation PLC Company Profile
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.